Helicobacter pylori strikes again: gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
Infection with Helicobacter pylori is common. Over 50% of the world's population is estimated to be colonized with the bacteria. The association between Helicobacter pylori and gastric mucosa-associated lymphoid tissue (MALT) lymphoma is well documented. Anti-Helicobacter pylori treatment and the successful eradication of the bacteria can potentially cure patients who test positive for the bacteria and who are diagnosed with low-grade gastric MALT lymphoma. The purpose of this article is to review the evidence implicating Helicobacter pylori as a causal pathogen for the development of gastric MALT lymphoma and to determine that anti-Helicobacter pylori therapy is an effective first-line treatment. The clinical presentation, endoscopic findings, diagnosis, staging, treatment, and follow-up of patients with gastric MALT lymphoma who are treated with anti-Helicobacter pylori therapy are also discussed.
s.swisher@comcast.net
Stephenie C
SC
Swisher
Alfonso J
AJ
Barbati
D000359:Aftercare; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D015984:Causality; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005756:Gastritis / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D005773:Gastroscopy; D020022:Genetic Predisposition to Disease; D016481:Helicobacter Infections / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D016480:Helicobacter pylori; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis / Q000235:genetics / Q000382:microbiology*; D009367:Neoplasm Staging; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000382:microbiology*
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors